<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331915</url>
  </required_header>
  <id_info>
    <org_study_id>LUC 09-003</org_study_id>
    <secondary_id>2009-014651-77</secondary_id>
    <nct_id>NCT01331915</nct_id>
  </id_info>
  <brief_title>Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients</brief_title>
  <acronym>THERAVAC</acronym>
  <official_title>Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <brief_summary>
    <textblock>
      In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin&#xD;
      coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.&#xD;
&#xD;
      The primary objective is to analyze the safety of the inreasing doses of vaccine.&#xD;
&#xD;
      The secondary objective is to document whether this vaccine can induce tumor regression in&#xD;
      immunized patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are three treatment cohorts and the inclusion of patients in governed by the&#xD;
      dose-limiting toxicities in the previous cohort.&#xD;
&#xD;
        -  the first three patients will receive a dose of 50 µg of Theravac®&#xD;
&#xD;
        -  second cohort of three patients will receive a dose of 150 µg Theravac®&#xD;
&#xD;
        -  the third cohort of three patients will receive a dose of 250 µg Theravac® and&#xD;
           eventually a total of 14 patients will complete the step with the highest dose.&#xD;
&#xD;
      All the patients will receive four immunizations every three weeks in two intradermal sites&#xD;
      and in two subcutaneous sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To analyze the safety and toxicity of increasing doses of Theravac® in patients with advanced metastatic melanoma</measure>
    <time_frame>the first 3 months of treatment</time_frame>
    <description>The toxicity will be assess after the treatment (3 months) for the first three patients of each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine whether these immunizations result in a detectable immune response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>PBMC will be obtained from the buffy-coat of 500 ml of venous blood or from 100 ml of venous blood collected before and after immunization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To document whether this vaccine can induce tumor regression in immunized patients.</measure>
    <time_frame>at week 12</time_frame>
    <description>The NEW RECIST criteria when applicable. For patients with only non-measurable lesion(s) at study entry, tumor response will be assessed descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Theravac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Theravac</intervention_name>
    <description>Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.&#xD;
Injection: intradermally and subcutaneously.</description>
    <arm_group_label>Theravac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven cutaneous, uveal or mucosal melanoma.&#xD;
&#xD;
          2. Melanoma must be metastatic. The origin of the primary could be cutaneous, uveal or&#xD;
             mucosal and any metastatic stage is accepted, except if brain or leptomeningeal&#xD;
             localizations are present, or if plasma LDH are elevated more than 1.5 normal upper&#xD;
             values (see also below).&#xD;
&#xD;
          3. HLA-A2 positive.&#xD;
&#xD;
          4. The melanoma must express the tyrosinase gene (positive RT-PCR on a frozen pre-immune&#xD;
             tumor sample) (see Appendix B).&#xD;
&#xD;
          5. At least one measurable or non-measurable tumor lesion (see Section 8.1).&#xD;
&#xD;
          6. Expected survival of at least 3 months.&#xD;
&#xD;
          7. Karnofsky performance scale ≥70 or WHO performance status of 0 or 1 (see Appendix C).&#xD;
&#xD;
          8. Vital laboratory parameters should be within normal range, except for the following&#xD;
             laboratory parameters, which must be within the ranges specified:&#xD;
&#xD;
             Lab Parameter Range Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l Granulocytes ≥ 1,500/µl&#xD;
             Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Serum creatinin ≤ 2.0 mg/dl or ≤ 177&#xD;
             μmol/l Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 μmol/l ASAT and ALAT ≤ 2 x the normal&#xD;
             upper limits LDH ≤ 1.5 x the normal upper limit.&#xD;
&#xD;
          9. Viral serology:&#xD;
&#xD;
               -  HIV (human immunodeficiency virus): negative antibodies.&#xD;
&#xD;
               -  HBV (hepatitis B virus): negative antigens; antibodies may be positive.&#xD;
&#xD;
               -  HCV (hepatitis C virus): negative antibodies.&#xD;
&#xD;
         10. Age ≥ 18 years&#xD;
&#xD;
         11. Able and willing to give valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with more than one regimen of systemic chemotherapy, combined or&#xD;
             not with non-specific immunotherapy such as interferon alpha or interleukins.&#xD;
             Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6&#xD;
             weeks for nitrosoureas and mitomycin C).&#xD;
&#xD;
          2. Previous treatment with a vaccine known or likely to contain the Tyrosinase.A2 epitope&#xD;
             YMDGTMSQV.&#xD;
&#xD;
          3. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3&#xD;
             congestive heart failure; myocardial infarction within the past six months; unstable&#xD;
             angina; coronary angioplasty within the past 6 months; uncontrolled atrial or&#xD;
             ventricular cardiac arrhythmias.&#xD;
&#xD;
          4. Active immunodeficiency or autoimmune disease. Vitiligo is not an exclusion criterion.&#xD;
&#xD;
          5. Other serious acute or chronic illnesses, e.g. active infections requiring&#xD;
             antibiotics, bleeding disorders, or other conditions requiring concurrent medications&#xD;
             not allowed during this study.&#xD;
&#xD;
          6. Other malignancy within 3 years prior to entry into the study, except for treated&#xD;
             non-melanoma skin cancer and cervical carcinoma in situ.&#xD;
&#xD;
          7. Allergy to kanamycin (used in the preparation of the recombinant protein) or to any&#xD;
             other aminoglycoside antibiotic.&#xD;
&#xD;
          8. Lack of availability for immunological and clinical follow-up assessments.&#xD;
&#xD;
          9. Participation in any other clinical trial involving another investigational agent&#xD;
             within 4 weeks prior to enrollment.&#xD;
&#xD;
         10. Pregnancy or breastfeeding.&#xD;
&#xD;
         11. Women of childbearing potential: Refusal or inability to use effective means of&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François Baurain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc, Centre du Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François Baurain, MD, PhD</last_name>
    <phone>0032 2 764 54 71</phone>
    <email>jean-francois.baurain@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline Gillain, MSc</last_name>
    <phone>0032 2 764 54 85</phone>
    <email>aline.gillain@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc, Centre du Cancer</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Baurain, MD, PhD</last_name>
      <phone>0032 2 764 54 71</phone>
      <email>jean-francois.baurain@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Jerome Degueldre, MSc</last_name>
      <phone>0032 2 764 75 33</phone>
      <email>jerome.degueldre@bru.licr.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-François Baurain, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>October 8, 2012</last_update_submitted>
  <last_update_submitted_qc>October 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Safety</keyword>
  <keyword>Theravac vaccine</keyword>
  <keyword>HLA-A2 typing</keyword>
  <keyword>Tyrosinase.A2 gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

